Novel approach gains traction in graft-versus-host disease

French biotechnology company MaaT Pharma (Euronext: MAAT) remains at the forefront of microbiome-based therapies, with new data on MaaT013 showing strong potential in acute graft-versus-host disease (aGvHD).

Presented at the ongoing annual meeting of the American Society of Hematology, the results, from 154 patients treated under a European early access program, show significant survival benefits in a condition with limited treatment options.

MaaT chief executive Hervé Affagard said: “The strong real-world data not only gives us confidence as we approach Phase III results but also validates our immune modulation approach. Success in GvHD could open doors to addressing other complex immune-mediated diseases.”